Why Is Inovio Pharmaceuticals (INO) Stock Up +17.21% Today?
Key Takeaways
- INO shares surged 17.21% during Thursday's regular session, trading at $0.9025 versus Wednesday's close of $0.77.
- Jefferies upgraded the stock to Buy from Hold and raised its price target to $3.00 from $1.80.
- Second-quarter results beat expectations, with a net loss of $0.07 per share compared with consensus estimates of a $0.25 per-share loss.
- The FDA review of INO-3107 remains on track for an October 30, 2026, PDUFA action date, with late-cycle review and pre-licensure inspections completed.
- Positive Phase 3 data from partner ApolloBio for VGX-3100 added validation for the company's DNA medicines platform.
- Traders are watching for FDA feedback on accelerated approval eligibility and planned label discussions in September.
Opening Summary
Inovio Pharmaceuticals, Inc. (INO) is a biotechnology company focused on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The stock rallied sharply on Thursday, with shares changing hands at $0.9025, up $0.1325, or 17.21%, from the prior session's closing price of $0.77. The move reflected a combination of a bullish analyst call and continued investor reaction to the company's second-quarter update, which highlighted progress toward a potential U.S. approval for its lead candidate, INO-3107.
Analyst Upgrade Triggers Buying
The most immediate catalyst behind Thursday's advance was an upgrade from Jefferies, which lifted INO to Buy from Hold and raised its price target to $3.00 from $1.80. The firm pointed to progress in the FDA review of INO-3107, an investigational treatment for recurrent respiratory papillomatosis, or RRP, following meetings with management. The upgrade signaled renewed conviction that the regulatory process remains on schedule and helped draw fresh buying interest into a stock that has experienced significant volatility. H.C. Wainwright reiterated a Neutral rating on the shares, underscoring that analyst views still reflect a range of opinions ahead of the binary regulatory decision.
FDA Review Progress for INO-3107
Investors continued to digest the company's regulatory update. Inovio said the FDA has completed its late-cycle review meeting and all scheduled pre-licensure inspections for INO-3107, with the target action date still set for October 30, 2026. The inspections covered clinical operations, drug manufacturing, in-house testing, and the company's delivery-device facility. Management said one observation was reported and that the company believes it has addressed the issue. The FDA has not yet indicated whether INO-3107 qualifies for accelerated approval, but the company expects label discussions to begin in September and is preparing for a potential U.S. launch through contract sales organization Syneos Health.
Second-Quarter Results and Pipeline Validation
The stock is also benefiting from follow-through after second-quarter results. Inovio reported a net loss of $6.0 million, or $0.07 per share, compared with a net loss of $23.5 million, or $0.61 per share, in the prior-year period and a consensus expectation for a $0.25 per-share loss. Operating expenses declined 19% year over year to $18.6 million. A portion of the narrower loss reflected a non-cash gain tied to warrant liability revaluation, which can introduce quarter-to-quarter volatility. Separately, the company highlighted positive top-line Phase 3 results from partner ApolloBio for VGX-3100 in cervical dysplasia in China, providing additional validation for its DNA medicine platform.
Market Context and Trading Activity
The surge was company-specific rather than a broad-market move, driven by the regulatory and analyst developments surrounding INO. Trading activity reflected a catalyst-driven repricing as investors reassessed the risk-reward setup ahead of the October PDUFA date. The advance extended a strong stretch for the stock, which had already gained roughly 14% over the prior five sessions through Wednesday's close. Even with the rally, shares remained well below the stock's 52-week high, and the move highlighted the outsized swings that can occur in small-cap biotechnology names with binary clinical and regulatory milestones.
What Comes Next for INO
The next major catalyst for INO is the FDA's decision on INO-3107, with a PDUFA target action date of October 30, 2026. Before that decision, investors will be watching for FDA feedback on the proposed confirmatory trial design and any signal on whether the agency views INO-3107 as eligible for accelerated approval. Label discussions are expected to begin in September, and the company continues to build commercial infrastructure ahead of a potential launch. Risks remain: accelerated approval is not guaranteed, the company is still burning cash, and management has projected its current resources will fund operations into late first quarter 2027. Competitive dynamics in RRP treatment and the potential need for additional financing add further uncertainty.
Trending AI Robots
Traders looking for systematic ways to track moves like this may find useful context on Tickeron's Trending AI Robots page. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this curated section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore different approaches to market momentum and volatility. Explore the page to see which AI-driven strategies are currently navigating today's conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
INO sees MACD Histogram crosses below signal line
INO saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 11, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 40 instances where the indicator turned negative. In 37 of the 40 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for INO moved out of overbought territory on September 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In 14 of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at 82%.
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INO as a result. In 66 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
INO moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for INO crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for INO entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where INO advanced for three days, in 183 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
INO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. INO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (27.701) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (437.542).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of synthetic vaccines and immune therapies for cancers and infectious diseases
Industry Biotechnology
Advertisement